Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiles of murine melanoma after treatment with STING agonist ADU-S100 [I]

ABSTRACT: Gene expression profiles of murine melanoma after treatment with STING agonist ADU-S100 [I]

PROVIDER: PRJNA1048459 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Gene expression profiles of murine melanomas after treatment with STING agonist ADU-S100 [II]

Project description:Two murine melanoma models (B16 and BPR) were treated with PBS or STING agonist ADU-S100 in vivo. Dose 1 was administered intratumorally on day 10, and a second dose was given on day 14. Tumors were collected 6 hours after the second dose and RNA was isolated. RNA was run on the Nanostring mouse PanCancer Immune Profiling Panel.

2023-12-09 | GSE249295 | GEO

Gene expression profiles of murine melanoma after treatment with STING agonist ADU-S100 [I]

Project description:Murine BPR melanomas were treated with either ADU-S100 or ADU-S100 + inhibitors of ARG2, COX2, and NOS2. Tumors were collected 7 days after treatment initiation and RNA was isolated and run on the Nanostring mouse Tumor 360 panel.

2023-12-09 | GSE249294 | GEO

Gene expression profiles of murine melanomas after treatment with STING agonist ADU-S100

Project description:Gene expression profiles of murine melanomas after treatment with STING agonist ADU-S100

| PRJNA1048456 | ENA

Gene expression profiles of murine melanomas after treatment with STING agonist ADU-S100 [II]

Project description:Gene expression profiles of murine melanomas after treatment with STING agonist ADU-S100 [II]

| PRJNA1048461 | ENA

Combination of EZH2 inhibitor and STING agonist in melanoma cell lines

Project description:In order to better understand the effects of combination treatment with EZH2 inhibitor and STING agonist in human melanoma cells, RNA sequencing was performed to explore transcriptome alteration.

2021-10-10 | GSE171538 | GEO

STING agonist alters the transcriptional profiles of HSPCs in melanoma-bearing mouse model

Project description:In order to better understand the effects of STING agonist diABZI on HSPCs, the LSKs and GMPs were sorted from mice BM and subjected to RNA sequencing to explore the transcriptome alteration after diABZI treatment.

2023-08-08 | GSE192927 | GEO

STING agonist alters the transcriptional profiles of HSPCs in melanoma-bearing mouse model

Project description:STING agonist alters the transcriptional profiles of HSPCs in melanoma-bearing mouse model

| PRJNA793834 | ENA

Combination of EZH2 inhibitor and STING agonist in melanoma cell lines

Project description:Combination of EZH2 inhibitor and STING agonist in melanoma cell lines

| PRJNA719921 | ENA

Transcriptome-wide identification of STING agonist programed B cells

Project description:We employed RNA-seq to study the transcriptomic change in B lymphocytes in response to STING agonist. Transcriptomic analysis of wild type and TMEM173–/– B cells stimulated with STING agonist revealed that the inflammatory response pathway enriched in 3'3'-cGAMP treated WT B cells but lacking in Tmem173-/-B cells comprised of a cluster containing inhibitory regulators, provoking STING signal to evade immune surveillance by inducing an immunosuppressive B cell population.

2022-08-10 | GSE199343 | GEO

STING activation promotes robust immune response and NK cell- mediated tumor regression in glioblastoma models

Project description:Immunotherapy has had a tremendous impact on cancer treatment in the past decade, with hitherto unseen responses at advanced and metastatic stages of the disease. However, the aggressive brain tumor glioblastoma (GBM) is highly immunosuppressive and remains largely refractory to current immunotherapeutic approaches. The cGAS-STING cytoplasmic double stranded DNA (dsDNA) sensing pathway has emerged as a next-generation immunotherapy target with potent local immune stimulatory properties. Here, we investigated the status of the STING pathway in GBM and the modulation of the brain tumor microenvironment (TME) with the STING agonist ADU-S100. Our data reveal the presence of STING in human GBM specimens, where it stains strongly in the tumor vasculature. We show that human GBM explants can respond to STING agonist treatment by secretion of inflammatory cytokines. In murine GBM models, we show a profound shift in the tumor immune landscape after STING agonist treatment, with massive infiltration of the tumor-bearing hemisphere with innate immune cells including inflammatory macrophages, neutrophils and NK populations. Treatment of established murine intracranial GL261 and CT-2A tumors by biodegradable ADU-S100-loaded intracranial implants demonstrated a significant increase in survival in both models and long-term survival with immune memory in GL261. Responses to treatment were abolished by NK cell depletion. This study reveals therapeutic potential and deep remodeling of the TME by STING activation in GBM and warrants the further examination of STING agonists alone or in combination with other immunotherapies such as cancer vaccines, CAR T cells, NK therapies or immune checkpoint blockade.

2022-06-28 | GSE206604 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data